

Special Issue

Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases in Patients with Diabetes Mellitus, 2nd Edition

Message from the Guest Editor

Diabetes mellitus (DM) has already evolved into an epidemic in developing countries, especially in the western world. It raises the risk of cardiovascular diseases (CVDs) 2- to 4-fold. The aim of this Special Issue is to attract high-quality papers that focus on drugs with a potential to contribute to CVD prevention and treatment in patients with diabetes. We also expect manuscripts providing evidence or summarizing the expanding cardiovascular benefits of current anti-diabetic medications or of candidate drugs. The anti-inflammatory agents and immunomodulators used in auto-immune diseases have opened a new era in the pharmaceutical treatment of patients with CVDs. In addition to this, other drugs targeting the main pathophysiological mechanisms of myocardial or vascular remodeling are also quite promising. Finally, herbal medicine remains a very promising source of drug candidates and requires further investigation. With all this in mind, there is an increasing number of drugs that could serve effectively in the primary and secondary prevention of CVDs in DM in order to improve the survival and the quality of life of patients with diabetes.

Guest Editor

Dr. Nikolaos Kadoglou
Medical School, University of Cyprus, 2029 Nicosia, Cyprus

Deadline for manuscript submissions

closed (25 March 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/224508

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)